What is the clinical evidence from this study?

Population: Hypertension and type 2b Fredricksen hyperlipidaemia (n=12). Intervention: Moxonidine. Primary outcome: 24-h ambulatory blood pressure (p=0.01).

What question did this study set out to answer?

To determine the effects of the centrally acting imidazoline type-1 receptor agonist moxonidine on detailed lipid and lipoprotein subfraction profiles in patients with hypertension and type 2b Fredricksen hyperlipidaemia.

May 28, 2004International Journal of Clinical Practice

Effect of moxonidine on lipid subfractions in patients with hypertension

View Full Paper

Ask AI

Bookmark

Key result

Moxonidine treatment significantly reduced 24-h ambulatory blood pressure by 10/5 mmHg (p=0.01) and LDL-C by 18% (p=0.03) in patients with hypertension and hyperlipidaemia.

Why the study?

Does moxonidine improve lipid profiles and blood pressure in patients with hypertension and type 2b hyperlipidaemia?

Key Points

To determine the effects of the centrally acting imidazoline type-1 receptor agonist moxonidine on detailed lipid and lipoprotein subfraction profiles in patients with hypertension and type 2b Fredricksen hyperlipidaemia.
Enrolled 12 patients with hypertension and type 2b Fredricksen hyperlipidaemia in an interventional trial evaluating moxonidine therapy, with 6 patients completing the study.
Assessed 24-hour ambulatory blood pressure, plasma lipid profiles, lipoprotein subfractions, and apolipoprotein (apo) A-1 and B concentrations using area under the curve analyses.
Moxonidine treatment achieved a 10/5 mmHg reduction in 24-h ambulatory blood pressure (p = 0.01).
Total cholesterol decreased by 10% (p = 0.04) and LDL-C decreased by 18% (p = 0.03), while triglycerides showed a non-significant 23% reduction and HDL-C increased non-significantly by 16%.
Lipoprotein subfraction analysis revealed a significant reduction in dense LDL apoB (p = 0.02) with increased buoyant LDL-C (p = 0.01), alongside a shift from dense HDL apoA-1 (p = 0.01) toward buoyant HDL apoA-1 (p = 0.01).

Structured PICO

Does moxonidine improve lipid profiles and blood pressure in patients with hypertension and type 2b hyperlipidaemia?

Population

12 patients with hypertension and type 2b Fredricksen hyperlipidaemia treated with moxonidine, with 6 completing the study.

Intervention

Moxonidine

Outcome

Detailed lipid and lipoprotein profiles (total cholesterol, LDL-C, triglycerides, HDL-C, apolipoproteins) and 24-h ambulatory blood pressuresurrogate

Main Result

p-value: p=0.01

Moxonidine may improve atherogenic lipid profiles and lower blood pressure in patients with hypertension and hyperlipidaemia.

Limitations

Small sample size (only 6 patients completed the study)

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Should not yet change practice; leaves open confirmation of dual benefits in randomized trials.

Cite This Study

Lumb et al. (2004) studied Hypertension and type 2b Fredricksen hyperlipidaemia (n=12). Moxonidine was evaluated on 24-h ambulatory blood pressure (p=0.01). Moxonidine treatment significantly reduced 24-h ambulatory blood pressure by 10/5 mmHg (p=0.01) and LDL-C by 18% (p=0.03) in patients with hypertension and hyperlipidaemia.

synapsesocial.com/papers/6a99c32c352e687f024d20f8 https://doi.org/10.1111/j.1368-5031.2004.00158.x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Effect of moxonidine on lipid subfractions in patients with hypertension

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Topics

Effect of moxonidine on lipid subfractions in patients with hypertension

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider